<DOC>
	<DOCNO>NCT01123473</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , epirubicin hydrochloride , cisplatin , fluorouracil , capecitabine , work different way stop growth tumor cell , either kill cell stop dividing . Lapatinib ditosylate may stop growth tumor cell block enzymes need cell growth . It yet know whether give combination chemotherapy together without lapatinib ditosylate effective treating patient cancer stomach gastroesophageal junction . PURPOSE : This randomized phase II trial study well epirubicin hydrochloride , cisplatin , fluorouracil capecitabine work give together without lapatinib ditosylate first-line therapy treat patient stomach cancer gastroesophageal junction cancer .</brief_summary>
	<brief_title>Epirubicin Hydrochloride , Cisplatin , Fluorouracil Capecitabine With Without Lapatinib Ditosylate First-Line Therapy Treating Patients With Stomach Cancer Gastroesophageal Junction Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine activity first-line treatment comprise epirubicin hydrochloride , cisplatin , fluorouracil capecitabine without lapatinib ditosylate patient adenocarcinoma stomach esophagogastric junction metastatic amenable curative surgery accord HER2 EGFR status . Secondary - To explore activity regimen patient HER2 negative FISH , HER2 positive IHC ( 2+ 3+ ) well patient HER2 positive negative FISH negative IHC ( 0 1+ ) , EGFR positive FISH IHC ( 2+ 3+ ) . - To assess concordance HER2 determination FISH IHC . OUTLINE : This multicenter study . Patients stratify accord institution combination EGFR/HER2 status determine fluorescence situ hybridization ( FISH ) immunohistochemistry ( IHC ) assay ( HER2 positive FISH/HER2 positive IHC 2/3+ v HER2 negative FISH/HER2 positive IHC 2/3+ v HER2 negative IHC 0/1+/EGFR positive FISH IHC 2/3+ ) . Patients randomize 1 2 treatment arm . - Arm I ( experimental ) : Patients receive epirubicin hydrochloride IV cisplatin IV day 1 ; fluorouracil IV continuously day 1-21 oral capecitabine twice daily day 1-21 ; oral lapatinib ditosylate daily day 1-21 . Treatment repeat every 21 day 6 course absence disease progression unacceptable toxicity . - Arm II ( control ) : Patients receive epirubicin hydrochloride , cisplatin , fluorouracil capecitabine arm I . Patients also receive oral placebo daily day 1-21 . Treatment repeat every 21 day 6 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow 8 week , every 3 month 2 year , every 6 month thereafter .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma stomach esophagogastric junction Metastatic disease OR amenable curative surgery Tissue material HER2 EGFR assessment must available Positive HER2 status immunohistochemistry ( IHC ) OR positive EGFR either fluorescence situ hybridization ( FISH ) IHC time randomization No clinical sign CNS involvement PATIENT CHARACTERISTICS : WHO performance status 01 WBC &gt; 3 x 10^9/L Absolute neutrophil count &gt; 1.5 x 10^9/L Platelet count &gt; 100 x 10^9/L Hemoglobin &gt; 9 g/dL Bilirubin ≤ 1.5 time upper limit normal ( ULN ) AST/ALT ≤ 3 time ULN ( ≤ 5 time ULN case liver metastasis ) Serum creatinine ≤ 2.0 mg/dL Creatinine clearance ≥ 60 mL/min Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 1 month completion study therapy LVEF normal MUGA scan ECHO No serious cardiac illness within past 6 month No previous concurrent malignancy except adequately treat conebiopsied carcinoma situ cervix basal cell carcinoma skin Able swallow retain oral medication No history evidence interstitial pneumonitis pulmonary fibrosis No uncontrolled infection serious illness , malabsorption syndrome , medical condition include chronic alcohol abuse , hepatitis , HIV , and/or cirrhosis No psychological , familial , sociological , geographical condition potentially hamper compliance study protocol followup schedule PRIOR CONCURRENT THERAPY : At least 12 month since prior neoadjuvant adjuvant chemotherapy No investigational drug 28 day prior first dose study treatment 30 day last dose study treatment At least 30 day since prior concurrent drug herbal constituent know inducer inhibitor CYP3A4 No prior palliative systemic chemotherapy No prior EGFR pathwaytargeting therapy ( e.g. , antibody tyrosine kinase inhibitor ) No concurrent traditional Chinese medicine No concurrent nondrug therapy radiotherapy ( pain relief ) surgery No concurrent anticancer therapy investigational agent No concurrent grapefruit juice</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>adenocarcinoma gastroesophageal junction</keyword>
	<keyword>adenocarcinoma stomach</keyword>
	<keyword>stage IIIA gastric cancer</keyword>
	<keyword>stage IIIB gastric cancer</keyword>
	<keyword>stage IIIC gastric cancer</keyword>
	<keyword>stage IV gastric cancer</keyword>
</DOC>